Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2019 (Quarterly Report)
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Signatory: Geoffrey Kempler, Executive Chairman (dated July 31, 2019)
Key Financial Metrics
The provided filing text serves as a cover sheet and does not contain the detailed financial data referenced in Appendix 4C. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided
- Profit/Loss: Not provided
- Cash Flow: Not provided
- Margins: Not provided
- Debt and Liquidity: Not provided
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. The document indicates that a quarterly report is included as Appendix 4C, but the content of that appendix is not present in the provided text.
Guidance, Outlook, and Risks
Guidance and Outlook: No management commentary, forward-looking guidance, or outlook is included in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Verify the full content of Appendix 4C (Quarterly Report) which is referenced but not included in this text.
- Confirm the company's current cash runway and burn rate, as no liquidity figures are present.
- Review the status of clinical trials or product development milestones, as no operational updates are provided.
- Check for any subsequent filings that may contain the detailed financial statements for the quarter ended July 31, 2019.